Tacrolimus is being increasingly used as an immunosuppressive agent in transplant recipients. The drug is metabolized by the cytochrome P-450 3A system, thus antimicrobials that inhibit or induce these enzymes can alter levels of tacrolimus in the bloodstream. Tacrolimus is potentially nephrotoxic and neurotoxic; the likelihood of toxicity rises as blood levels of the drug increase. Increased tacrolimus levels and subsequent toxicity have been produced by a number of antimicrobial agents that inhibit the cytochrome P-450 3A system. Conversely, drugs with the potential to induce the cytochrome P-450 3A system can reduce the levels of tacrolimus in the blood, leading to increased risk of acute rejection in transplant recipients. Antimicrobial agents that can have adverse effects on renal function may add to the nephrotoxicity of tacrolimus. The potential for drug interactions should be reviewed before antimicrobial agents are prescribed to patients treated with tacrolimus.
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Tacrolimus is being increasingly used as an immunosuppressive agent in transplant recipients. The drug is metabolized by the cytochrome P-450 3A system, thus antimicrobials that inhibit or induce these enzymes can alter levels of tacrolimus in the bloodstream. Tacrolimus is potentially nephrotoxic and neurotoxic; the likelihood of toxicity rises as blood levels of the drug increase. Increased tacrolimus levels and subsequent toxicity have been produced by a number of antimicrobial agents that inhibit the cytochrome P-450 3A system. Conversely, drugs with the potential to induce the cytochrome P-450 3A system can reduce the levels of tacrolimus in the blood, leading to increased risk of acute rejection in transplant recipients. Antimicrobial agents that can have adverse effects on renal function may add to the nephrotoxicity of tacrolimus. The potential for drug interactions should be reviewed before antimicrobial agents are prescribed to patients treated with tacrolimus.
Tacrolimus (previously known as FK 506) is a new immunodrugs [8] , in that the inhibition of T cell proliferation by tacrolimus may be antagonized or overenhanced by interactions with suppressive drug that is widely used both as a primary immunosuppressive agent and as rescue therapy in patients undergoing other drugs.
Infections are the major cause of morbidity and mortality organ transplantation [1] . It is a macrolide produced by Streptomyces tsukubaensis. Multicenter trials in the United States and after transplantation, and thus antimicrobial agents are widely used in patients who have received organ transplants. We reEurope have demonstrated that the use of tacrolimus in liver transplant recipients has been associated with significantly view the interactions between tacrolimus and the complete range of antimicrobial agents. Interactions between tacrolimus lower rejection rates than the use of cyclosporine [2, 3] . Patients receiving tacrolimus also have lower requirements for concurand drugs other than antimicrobial agents will not be discussed herein, as recent reviews of these interactions are available rent immunosuppression, e.g., with corticosteroids or OKT3 [2, 3] . Other advantages of tacrolimus over cyclosporine include a elsewhere [9, 10] . Reviews of interactions between the older immunosuppressive agents and antimicrobial agents are also lesser likelihood that gingival hyperplasia, hirsutism, coarsening of the facial features, and hypertension will occur. available elsewhere [9, 11] . However, like cyclosporine, tacrolimus is nephrotoxic and neurotoxic and has a narrow therapeutic window. There is a correlation between increased blood levels of tacrolimus and Methods nephrotoxicity [4, 5] and severe neurotoxicity [4, 6] . Hence, the use of tacrolimus requires knowledge of potential drug To evaluate drug interactions between tacrolimus and antimiinteractions that may lead to increased blood levels of the crobial agents, we initially performed a MEDLINE search of drug. Conversely, interactions with other drugs may result in the literature published between 1966 and 1997 by using the diminished serum concentrations of tacrolimus, thereby inkeywords tacrolimus and drug interactions. In addition, we creasing the risk of organ rejection [7] .
searched MEDLINE by using the keywords tacrolimus in comUse of other drugs with adverse effects similar to those of bination with the individual antimicrobial agents (e.g., clartacrolimus (i.e., nephrotoxicity or neurotoxicity) may lead to ithromycin). TOXLINE was also searched for drug interactions additive or even synergistic toxicity when they are used in involving tacrolimus. We reviewed the references cited in the combination with tacrolimus. This toxicity is not due to a pharretrieved articles for other relevant articles. Recent issues of macokinetic interaction but rather to similar effects at the site journals relevant to infectious diseases and transplantation were of the end-organ (brain or kidney).
manually searched for articles that may not yet have been Recent concern has also been expressed about the possibility indexed in MEDLINE or TOXLINE. Proceedings of both inof immunologic interactions between tacrolimus and other fectious diseases and transplantation conferences held between 1990 and 1996 were also searched for relevant articles. The manufacturers of tacrolimus (Fujisawa USA, Deerfield, IL) were contacted for any unpublished reports of relevant interac-larly when they are used at high doses in patients with impaired renal function [32] , or when imipenem is used in patients with Mechanisms and experimental models. The majority of blactam antibiotics undergo little metabolism and are excreted CNS abnormalities [33] . A number of reviews of tacrolimusinduced neurotoxicity have been published [34, 35] , but none as intact molecules via the kidney [23] . Hence, they are unlikely to interfere with the metabolism of tacrolimus, which is mainly have suggested that neurotoxicity is more common in patients receiving concurrent b-lactams. metabolized by the cytochrome P-450 system [24, 25]. The effect of two individual cephalosporins on the metabolism of Interpretation and recommendations. Gram-positive organisms are emerging as the leading cause of bacterial infection tacrolimus by the human cytochrome P-450 system has been tested [26] ; neither drug had any major effect. Cefixime at in organ transplant recipients. Staphylococcus aureus and Staphylococcus epidermidis are the foremost causes of bacterconcentrations of 10 mmol and 100 mmol inhibited tacrolimus metabolism 4.4% and 10.2%, respectively. Cefotaxime at conemia in organ transplant recipients [36] , and enterococci are an increasingly important problem in liver transplant recipients. centrations of 10 mmol and 100 mmol stimulated tacrolimus metabolism 16.6% and 9.7%, respectively.
We recommend that doses of b-lactams be identical to those used to treat infections with such organisms in patients without Clinical studies. Renal toxicity can occasionally occur with b-lactam antibiotics, particularly the penicillins [27] . This toxtransplants who have comparable renal function. There is no current indication to avoid the concurrent use of nafcillin and icity is usually in the form of interstitial nephritis, as is most often seen with drugs such as methicillin [28] . There have tacrolimus, despite the limited data on an interaction with cyclosporine. Similarly, the data on the nephroprotective effect been no published reports describing an increased likelihood of nephrotoxicity when tacrolimus and b-lactam antibiotics are of cilastatin when used in combination with cyclosporine are too preliminary to extend to tacrolimus, and we do not recomused simultaneously. The results of one study suggest that nafcillin potentiates cyclosporine nephrotoxicity in lung transmend concurrent use of these drugs soley for a purported nephroprotective effect. plant recipients [29] . In this study there was no difference in cyclosporine levels between patients who received nafcillin and
The intravenous formulation of tacrolimus contains alcohol, and there is potential for interaction between cephalosporins those who did not. Although it has been suggested that nafcillin may enhance the hepatic metabolism of cyclosporine [30] , there containing a methylthiotetrazole group and alcohol, producing a disulfiram-like reaction [37] . This has not been described are no data suggesting that such an interaction occurs with tacrolimus. It is of interest that the results of a placebo-conwith intravenous tacrolimus, but physicians need to bear this potential in mind when cefamandole, cefoperazone, cefotetan, trolled, single-blinded study suggested that imipenem/cilastatin moxalactam, cefmetazole, or cefmenoxime are coadministered with intravenous tacrolimus. Mechanisms and experimental models. Vancomycin and teicoplanin undergo minimal metabolism and are eliminated Erythromycin [13 -15] Increased tacrolimus levels, with subsequent nephrotoxicity from the body almost exclusively by glomerular filtration. is vancomycin alone, there have been no studies suggesting rolides and tacrolimus in vitro or in animal models. Erythromycin, clarithromycin, roxithromycin, dirithromycin, and trioleanthat the specific combination of vancomycin and tacrolimus has domycin share a 14-membered macrolcyclic lactone ring a particular propensity for causing excessive nephrotoxicity.
structure. Azithromycin differs in having a 15-membered ring Teicoplanin is thought to be less nephrotoxic than vancomycin
[40]. The 14-membered ring macrolides are known to form [39]; the combination of teicoplanin/tacrolimus has not been inactive complexes with cytochrome P-450 3A isozymes and studied.
therefore inhibit the metabolism of other drugs [41] . TacroliInterpretation and recommendations. As previously stated, mus is primarily metabolized by this cytochrome P-450 3A serious staphylococcal infections are common in transplant resystem [24, 25] . Several authors have shown that the 14-memcipients [36] . If vancomycin or teicoplanin are indicated, attenbered-ring macrolides inhibit the metabolism of tacrolimus by tion should be paid to using them in dosages appropriate to a both the hepatic and small intestinal cytochrome P-450 3A patient's renal function. In particular, if tacrolimus-induced subfamily in vitro [26, 42, 43] . For example, erythromycin at nephrotoxicity occurs, dosage reduction may be required. a concentration of 100 mmol inhibited the cytochrome P-450 3A -mediated metabolism of tacrolimus by 32.5% [26] .
Interactions with Macrolide Antibiotics (Erythromycin,
Animal studies have also confirmed this effect on tacrolimus Roxithromycin, Clarithromycin, and Azithromycin) metabolism. Rui et al. [44] showed that acute treatment with Mechanisms and experimental models. Several studies oral erythromycin (50 mg/[kgrd]) increased tacrolimus concentrations threefold in male Wistar rats. have been performed to examine the interaction between mac- No studies have been performed on the interaction between Clinical studies. Several case reports on the clinical impact of interaction between 14-membered-ring macrolides, such as the 15-membered ring macrolide, azithromycin, and tacrolimus in vitro. However, it is known that azithromycin does not share erythromycin and clarithromycin, and tacrolimus have appeared [13 -16] . In contrast, there are no case reports of such the property of formation of complexes with cytochrome P-450 3A isozymes, and hence, seems less likely to interfere with an interaction with azithromycin. Jensen et al. [13] described a 62-year-old male who had the metabolism of drugs metabolized by this pathway. Amacher et al. [45] showed that, unlike erythromycin, azithromycin did marked deterioration in renal function that coincided with the coadministration of erythromycin and tacrolimus after renal not induce or inactivate the hepatic cytochrome P-450 system in Sprague-Dawley rats.
transplantation. Shaeffer et al. [14] described a 39-year-old male who similarly had a rise in plasma tacrolimus levels and Erythromycin, like tacrolimus, has a suppressive effect on human lymphocyte proliferation and potentiates the action of deterioration in renal function when given oral erythromycin after liver transplantation. Furlan et al. [15] reported two cases tacrolimus in vitro [46] . The clinical relevance of this action is unknown.
of acute renal impairment associated with the coadministration [26] , who showed Wolter et al. [16] described an interaction between tacrolimus that the aminoglycoside, kanamycin, had a negligible effect on and clarithromycin in a 45-year-old female renal transplant tacrolimus metabolism. Concentrations of 10 mmol and 100 recipient.
mmol resulted in inhibition of tacrolimus metabolism by 5.6% Interpretation and recommendations. Macrolide antibiotand 8.8%, respectively. ics are particularly useful in the treatment of respiratory tract However, both tacrolimus and aminoglycosides are known infections, especially those due to organisms such as Mycoto produce nephrotoxicity. Aminoglycosides are known to proplasma pneumoniae and Legionella species. Transplant recipiduce damage to the proximal tubular cells, although the precise ents appear to be at high risk for legionellosis [47] . However, mechanism by which this leads to a decrease in the glomerular since the 14-membered ring macrolides have such marked infiltration rate is unknown [50] . Tacrolimus can also produce teractions with tacrolimus, this group of drugs should probably degenerative changes in the proximal tubular epithelium [51] , be avoided in a patient receiving tacrolimus. As the 15-membalthough decreased renal blood flow due to constriction of ered ring macrolide, azithromycin, does not interact with the preglomerular vessels may also be important in the pathogenecytochrome P-450 3A system in vitro, we hypothesize that this sis of nephrotoxicity [52, 53] . It is not known whether there drug may not have a significant interaction with tacrolimus.
is synergistic action between tacrolimus and aminoglycosides We would therefore prefer its use to other macrolides for the in the proximal tubular cells, which could lead to a greater empirical treatment of community-acquired pneumonia. Howthan additive nephrotoxic effect. ever, despite anecdotal experience that the combination is safe, Clinical studies. No clinical studies in which assessment the interaction between tacrolimus and azithromycin has not could be made of interactions between aminoglycosides and been formally tested in vitro.
tacrolimus have been performed. It should be noted that despite similar reasoning and anecInterpretation and recommendations. There is no doubt dotal experience with the azithromycin-cyclosporine combinathat aminoglycosides and tacrolimus are nephrotoxic agents. It tion, a dramatic elevation in cyclosporine blood concentrations is not known whether the combination of the two is likely to has been described in one patient [48] . While azithromycin cause greater impairment of renal function than the use of either may be the macrolide of choice for patients receiving tacrolidrug alone. Despite their potential for toxicity, aminoglycosides mus, until more data are available, we would advise close may remain useful agents in the management of serious pseumonitoring of tacrolimus levels and renal function when the domonal infections in transplant recipients. The nephrotoxicity two drugs are given in combination. Quinolones are active in of aminoglycosides can be minimized by giving them once vitro against Legionella species [49] , lack significant interacdaily rather than in multiple daily doses [54] and by restricting tion with tacrolimus, and may therefore be more suitable agents the duration of treatment to 5 or 7 days at most [55] . However, than macrolides for the treatment of legionellosis and other serious enterococcal infections should continue to be treated atypical pneumonias in transplant recipients [47] .
with multiple daily doses of an aminoglycoside (in combination with an appropriate cell-wall-active antibiotic). We would rec- Mechanisms and experimental models. Rifampin is a wellMechanisms and experimental models. The metabolism of documented, strong inducer of the cytochrome P-450 isoenzymes quinolones varies according to the individual drug, but some [63] . Recent data suggest that while rifampin causes a significant have been known to inhibit microsomal cytochrome P-450 increase in cytochrome P-450 3A activity, rifabutin may not have enzymes [49] . However, enoxacin, the quinolone with greatest this effect [64] . Since tacrolimus is metabolized by the cytochrome effect on the cytochrome P-450 system [49] , was found to P-450 3A system, it would therefore be expected that coadminishave virtually no in vitro effect on tacrolimus metabolism by tration of rifampin, but to a lesser extent rifabutin, would result cytochrome P-450 3A [26] .
in diminished tacrolimus levels. This has been shown experimenConcern has been expressed that there may be an immunotally in rats [65] . The administration of pyrazinamide, ethambutol, logic interaction between ciprofloxacin and immunosuppresand isoniazid would not be expected to have significant effect on sive drugs [8] . Ciprofloxacin has been shown to induce hyperthe cytochrome P-450 3A system. production of IL-2 by human peripheral blood lymphocytes Clinical studies. Furlan et al. [15] described a 10-year-old in vitro [56] . Tacrolimus exerts its clinical effect by ultimately boy in whom the coadministration of rifampin and tacrolimus causing an inhibition of T cell proliferation due to an inhibiafter liver transplantation resulted in a decrease in the tacrolition in IL-2 production by T cells [57] . Kelly et al. [58] mus level below the limit of quantitation within 2 days. The addressed this finding by incubating peripheral blood lymphotacrolimus dose needed to be doubled to maintain detectable cytes with 1% phytohemagglutinin in the presence of ciwhole-blood levels. Kiuchi et al. [22] described a 10-monthprofloxacin, with and without tacrolimus. Ciprofloxacin alone, old girl who received a living-related liver transplant and develat a high concentration (20 -80 mg/L), did produce a marked oped a liver abscess due to Mycobacterium tuberculosis. Treatincrease in IL-2 production. The addition of tacrolimus led ment with isoniazid, rifampin, ethambutol, and streptomycin to a reduction in IL-2 production.
were started. She developed severe graft rejection and the vanDespite this increase in IL-2 induced by ciprofloxacin, ciishing bile duct syndrome. The tacrolimus levels decreased to profloxacin in high concentrations actually produced a deapproximately one-tenth of baseline levels. crease in peripheral blood lymphocyte proliferation [58] . This
Interpretation and recommendations. As a consequence of antiproliferative effect was even greater when tacrolimus and the use of immunosuppressive agents such as tacrolimus, recipciprofloxacin were incubated together. However, it was conients of organ transplants are at increased risk of infection with cluded [58] that these in vitro effects are observed at very M. tuberculosis, and possibly, nontuberculous mycobacteria high, therapeutically irrelevant ciprofloxacin concentrations [66 -68] . Coadministration of rifamycins and tacrolimus may (e.g., 80 mg/L), whereas in vivo peak concentrations of cibe difficult, since enzyme induction with marked reduction in profloxacin given every 12 hours orally for 5 days are far tacrolimus levels may result. While the subsequent reduction lower (Ç2.5 mg/L) [59] . Kelly et al. [58] believe that it is in immunosuppression may be beneficial in terms of treating unlikely that at clinically achievable concentrations, cithe mycobacterial infection, this benefit may be offset by the profloxacin will enhance or counteract the tacrolimus-induced increased risk of acute rejection [7, 22] . immunologic changes.
The dosage of ethambutol needs to be reduced if renal imClinical studies. There have been no clinical studies depairment due to tacrolimus therapy or other causes occurs. scribing an interaction between tacrolimus and quinolones.
Treatment of drug-resistant tuberculosis or infections caused Interpretation and recommendations. There are few data by atypical mycobacteria is difficult in the patient receiving suggesting a high likelihood of interaction between quinolones tacrolimus. Drugs that are unlikely to have significant interacand tacrolimus in transplant recipients. However, despite the tions and that can be considered options include pyrazinamide, fact that there had been a similar lack of theoretical basis for streptomycin, amikacin, ofloxacin, and ciprofloxacin. interaction between quinolones and cyclosporine, three case reports appeared that described increases in cyclosporine concentrations, with subsequent nephrotoxicity [60 -62] . We
Interactions with Miscellaneous Antibiotics
would recommend routine dosing of quinolones in the transplant recipient receiving tacrolimus, although the dose or dosThere are few in vitro studies and no clinical studies detailing ing frequency must be reduced for ciprofloxacin, norfloxacin, the experience with other antibiotics and tacrolimus. However, ofloxacin, enoxacin, or lomefloxacin when a patient's creatisome generalizations can be made. nine clearance decreases to õ30 mL/min. Finally, quinolones, Quinupristin/dalfopristin, an antibiotic combination frequently like tacrolimus, can sometimes be neurotoxic [49] . When the active against vancomycin-resistant enterococci (VREF), is symptoms of neurotoxicity fail to abate in response to a reducstructurally similar to macrolide antibiotics [69] . However, detion in the dose of tacrolimus, they may be managed by cessaspite the frequent use of this combination in liver transplant centers where VREF is a problem, to our knowledge, there tion of the concomitant administration of quinolones. Trimethoprim-sufamethoxazole (TMP-SMZ), in doses used as prophylaxis for Pneumocystis carinii pneumonia, has not
Mechanisms and experimental models. In vitro and animal studies have indicated that tacrolimus actually possesses direct been shown to interact with tacrolimus. High-dose TMP-SMZ is not known to interfere with the metabolism of tacrolimus but antifungal activity [73 -75] . However, the overwhelming effect of immunosuppression leads to fungal proliferation at higher may cause renal impairment due to a number of mechanisms, including interstitial nephritis. In addition, a reduction in the doses and thus outweighs the antifungal activity of the drug. It is not known whether any synergy, in terms of antifungal dose of TMP/SMZ is required if a patient's creatinine clearance decreases to õ30 mL/min. effect, exists between tacrolimus and azole drugs. It is well known that pharmacokinetic interactions occur Minocycline has been shown to have a trivial effect on tacrolimus metabolism by the cytochrome P-450 3A isozymes between tacrolimus and the azoles. Miconazole, ketoconazole, fluconazole, and itraconazole have been reported to inhibit both [26] . The effects of tetracycline and doxycycline on the metabolism of tacrolimus by the cytochrome P-450 3A isoenzymes liver and the small intestine microsomes that metabolize tacrolimus [26, 42, 43, 76] . Ketoconazole is the most potent inhibitor have not been studied. The doses of tetracycline and minocycline need to be reduced, or the drugs need to be discontinued, of tacrolimus metabolism in vitro [76] . However, in a study of rats, acute treatment with fluconazole increased tacrolimus in patients with renal impairment. The doses of doxycyline do not need adjustment in patients with renal dysfunction.
concentrations by fourfold, whereas treatment with ketoconazole increased tacrolimus concentrations by only twofold [44] . Lincomycin had approximately half as much inhibitory effect on tacrolimus metabolism as erythromycin (15.1% inhibiClinical studies. Mieles et al. [17] reported a significant interaction between clotrimazole troches and tacrolimus, which tion with lincomycin vs. 32.5% with erythromycin) [26] . An interaction between clindamycin and tacrolimus has not been resulted in acute renal impairment in a 55-year-old man after liver transplanation. Because clotrimazole is poorly absorbed, studied or observed. We use routine doses of clindamycin or lincomycin in transplant recipients but observe renal function the authors explained this interaction as being due to interaction with cytochrome P-450 enzymes in the enterocytes of the paand tacrolimus levels closely.
Metronidazole has no known metabolic interactions with tient's jejunal mucosa. Assan et al. [18] described a clinically important interaction tacrolimus. The intravenous formulation of tacrolimus contains dehydrated alcohol, and hence, a disulfiram-like reaction is between fluconazole and tacrolimus after liver transplantation in a 57-year-old female; the tacrolimus levels were elevated, theoretically possible when the two drugs are coadministered, although this has not been described. and acute renal impairment occurred. The same patient was challenged with ketoconazole 1 year later when she was in a Fosfomycin has been shown to have a minimal effect on tacrolimus metabolism by the cytochrome P-450 system [26] . stable clinical condition, and the tacrolimus levels were again found to be elevated. Vincent et al. [19] described two children However, an immunologic interaction has been observed in vitro [71] . Combined treatment with fosfomycin and tacrolimus who developed nephrotoxicity after liver transplantation when they were given intravenous fluconazole and tacrolimus. Mañez produced at least additive suppression of T cell proliferation.
Fusidic acid, an antistaphylococcal antibiotic, has some imet al. [20] described 20 transplant patients who were given fluconazole and tacrolimus; these investigators showed that the munosuppressive properties; the presence of fusidic acid has been shown to result in a decrease in production of IL-1 and effect of fluconazole on tacrolimus levels was dose dependent. These authors used a median dosage reduction of 56% (range, IL-2 from activated blood mononuclear cells [72] . The clinical significance of this effect is uncertain but is unlikely to be a 0 -88%) to keep trough plasma tacrolimus concentrations below 2 ng/mL. Osowski et al. [21] described 15 patients who concern if the drug is used topically.
Mupirocin, used topically, is not expected to have any interreceived intravenous fluconazole (400 mg/d) in combination with intravenous tacrolimus. Mean baseline whole-blood levels action with tacrolimus.
Chloramphenicol is metabolized by the cytochrome P-450 of tacrolimus rose 16%, and two patients developed an increase in serum creatinine greater than twice baseline. system and hence has potential for interaction with tacrolimus. In one study, the administration of chloramphenicol increased Interpretation and recommendations. Fungal infections are an important cause of morbidity and mortality in transplant the blood concentration of tacrolimus in transplant recipients [65] , although the extent of this increase was not reported.
recipients. We urge caution when the azoles and tacrolimus are administered together. The dose of tacrolimus should be We recommend close observation of tacrolimus levels and the serum creatine level if the two drugs are coadministered.
halved when an azole is coadministered [20] . apine may induce hepatic cytochrome P-450 enzymes [79] , and Amphotericin B has been shown to have an insignificant reduced serum tacrolimus levels would be expected. effect on the metabolism of tacrolimus [26] . However, amphoClinical studies. No clinical studies reporting an interactericin B is well known to be nephrotoxic. Vincent et al. [19] tion between tacrolimus and antiretroviral drugs have been described two children who developed severe acute renal imperformed. pairment (creatinine clearance decreased to 20 mL/min) when Interpretation and recommendations. The possible interacthey received intravenous amphotericin B and tacrolimus after tion between tacrolimus and antiretroviral drugs is relevant, liver transplantation. In these cases, renal function returned to since a number of organ transplant recipients have been found normal within days of stopping the antifungal therapy. It is to be infected with HIV [80] . If antiretroviral therapy is given, not known whether there is a more than additive effect when ritonavir and nevirapine should probably be avoided if possible. tacrolimus and amphotericin B are used together. Daily moniCombination therapy with a regimen such as zidovudine, lamitoring of serum creatinine is probably warranted for patients vudine, and indinavir would appear relatively safe and free receiving both drugs.
from major effects on tacrolimus levels. However, as published Liposomal preparations of amphotericin B are less nephroexperience with the use of antiretroviral drugs and tacrolimus toxic than the conventional formulation, although no survival is nonexistent, we recommend close monitoring of tacrolimus benefit has been demonstrated with these agents [77] . Vincent levels and serum creatinine on initiation of such therapy, or at et al. [19] observed a child after liver transplantation who any time therapy is changed. An issue of lesser concern is received a long course of liposomal amphotericin B and did the suggestion that tacrolimus may itself be an inhibitor of not develop renal impairment. White et al. [77] reported a cytochrome P-450 3A4 isoenzymes [81] . Because the protease double-blind, randomized trial comparing amphotericin B colinhibitors are metabolized by this enzyme system, the serum loidal dispersion (ABCD) with the conventional formulation levels of these drugs may be increased when tacrolimus is in 77 neutropenic adult patients who received either tacrolimus administered. It is not known whether this increase would neor cyclosporine. The rate of renal toxicity was 27.8% among cessitate reduction in the dose of the protease inhibitor. At this patients treated with ABCD, as compared with 67.6% among stage, we favor use of standard dosage regimens, with close patients given the conventional preparation. Mortality did not observation for toxicity from the protease inhibitor. differ in the two treatment groups.
Zidovudine, didanosine, zalcitabine, stavudine, and lamivuFlucytosine is not known to interact with tacrolimus. The dine are predominantly excreted through the kidneys. Adjustdosage of flucytosine should be reduced if tacrolimus-induced ment in the dosages of these drugs is required if tacrolimusrenal impairment occurs.
induced nephrotoxicity occurs. The dosages of lamivudine, zalNystatin, applied topically or as a swish-and-swallow regicitabine, stavudine, and didanosine should be reduced when a men, would not be expected to interact with tacrolimus.
patient's creatinine clearance decreases to õ40 -50 mL/min, Griseofulvin can frequently produce headaches, which may whereas adjustment in the dosage of zidovudine is required be confused with tacrolimus-induced neurotoxicity. The effects only if dialysis is needed. of alcohol (which is contained in the intravenous formulation of tacrolimus) may be potentiated by griseofulvin. No clinically significant interactions have been reported.
Interactions with Other Antiviral Agents
Terbinafine is unlikely to produce changes in tacrolimus metabolism. The use of terbinafine in patients whose creatinine Acyclovir has a minimal effect on the metabolism of tacroliclearance is õ50 mL/min is not recommended. mus in vitro [26] . Dosage reductions of acyclovir are indicated if tacrolimus-induced renal impairment (creatinine clearance, õ50 mL/min) occurs. Neurotoxicity, resembling that produced
Interactions with Antiretroviral Agents
by tacrolimus, can occur if this dosage reduction is not performed. Mechanisms and experimental models. The protease inhibitors (ritonavir, indinavir, saquinavir, and helfinavir) are metabValaciclovir, the prodrug of acyclovir, would not be expected to have an effect on the metabolism of tacrolimus. There are olized in the liver by the cytochrome P-450 3A4 isoenzyme. In addition, they can act as inhibitors of cytochrome P-450-no specific recommendations for the dosing of valaciclovir in / 9c40$$de19 11-03-97 21:01:02 cida UC: CID organ transplant recipients because drug trials in this patient Guérin) vaccine, yellow fever vaccine, and measles, mumps, and rubella virus vaccine. population have not been completed.
Famciclovir is not metabolized by the cytochrome P-450 system and is not expected to interact with tacrolimus. Dosage adjustment should be performed when a patient's creatinine Discussion clearance is õ60 mL/min.
Ganciclovir is widely used in transplant recipients, but no The use of tacrolimus is increasing, and infectious diseases physicians need to be aware of its potential interaction with formal drug interaction studies with tacrolimus have been performed. No pharmacokinetic interaction would be expected.
antimicrobial agents. Most interactions are based on alteration in the metabolism of tacrolimus by the cytochrome P-450 3A Ganciclovir dose should be reduced if tacrolimus-induced renal impairment occurs.
system. Macrolides (with the possible exception of azithromycin), azoles, chloramphenicol, quinupristin/dalfopristin, and Foscarnet is a nephrotoxic drug; however, it is not known whether tacrolimus nephrotoxicity is potentiated when the two protease inhibitors may form inactive complexes with cytochrome P-450 3A enzymes and therefore inhibit the metabolism agents are used together.
Inhaled ribavirin should not have an interaction with the of tacrolimus. As a result, serum tacrolimus levels may rise, increasing the risk of nephrotoxicity or neurotoxicity. Conmetabolism of tacrolimus.
Amantadine does not have a known interaction with tacroliversely, rifampin and nevirapine may induce the cytochrome P-450 3A system, leading to reduction in serum tacrolimus mus but can produce CNS effects similar to those of tacrolimus neurotoxicity. In addition, dosage reduction is necessary if a levels. This reduction may increase the risk of organ rejection.
In view of the interactions described above, treatment of patient's creatinine clearance is õ50 mL/min.
IFN-a can interfere with the metabolism of some drugs by pneumonia, tuberculosis, HIV infection, and infections with vancomycin-resistant enterococci or with fungi is more difficult reducing the activity of hepatic cytochrome P-450 enzymes. However, the relevance of this action to the metabolism of in the transplant recipient. One management option is to prescribe an antimicrobial agent of a different class (e.g., a quinotacrolimus has never been studied. IFN-a can also affect the CNS in ways similar to those observed with tacrolimus.
lone instead of a macrolide for treatment of suspected legionella pneumonia). Alternative strategies include reduction in dosage of the antimicrobial agent (or tacrolimus) or close monitoring
Interactions with Antiparasitic Agents of serum tacrolimus levels. We have found that knowledge of likely interactions can allow anticipatory changes in dosing or Dapsone is a substrate for the cytochrome P-450 3A isoenzyme, as is tacrolimus. Dapsone inhibits the metabolism of in the frequency of serum monitoring for tacrolimus levels. For example, a transplant recipient treated for tuberculosis with tacrolimus to a moderate degree [76] , although the extent may not be sufficient to have clinical impact.
a rifampin-containing regimen may need a larger dosage of tacrolimus to prevent organ rejection than would a transplant Pentamidine, when given as an aerosol, is unlikely to have an interaction with tacrolimus. Renal failure occurs frequently recipient who is not receiving an antituberculous regimen. The potential for tacrolimus toxicities to resemble those prowhen intravenous pentamidine is administered, and close monitoring for an enhancement of this effect by tacrolimus should duced by a variety of antimicrobial agents (and vice versa) also needs to be considered. Nephrotoxicity and neurotoxicity are be performed.
Atovaquone has little potential for interaction with tacrolithe major considerations. The neurotoxicity associated with tacrolimus may resemble that seen with high doses of b-lacmus, as atovaquone has no impact on the cytochrome P-450 system. tams, quinolones, or amantadine. Although potentiation of toxicity has not been studied with respect to most drugs, we conChloroquine, quinidine, and mefloquine are substrates for the cytochrome P-450 3A system. Quinidine has been shown sider potentiation of nephrotoxicity a possible risk when amphotericin B, aminoglycosides, or foscarnet are used in pato moderately inhibit tacrolimus metabolism in vitro [76] . However, no clinical interactions have been reported between any tients receiving tacrolimus. Finally, reduction of the dosages of many antimicrobial agents is necessary when tacrolimusof these antimalarials and tacrolimus. We recommend the usual dosages of antimalarials for prophylaxis or treatment of mainduced renal dysfunction occurs. Iatrogenically immunosuppressed patients are likely to relaria, but we advise monitoring of tacrolimus levels before travel to a malarious region.
ceive a variety of antimicrobial agents in the posttransplantation period. Like cyclosporine, tacrolimus has the potential to interact with many of these drugs. However, since the majority
Interactions with Vaccines
of these interactions are predictable, adverse effects from such interactions should usually be avoidable. As new antimicrobial The use of live vaccines is contraindicated in patients receiving tacrolimus. These live vaccines include typhoid vaccine, agents become available, studies on their potential for interaction with tacrolimus should be performed. oral live trivalent poliovirus vaccine, BCG (bacille Calmette-
